Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• 3.1.1 Patients must have a histologically confirmed HPV-related OPSCC, confirmed by HPV insitu hybridization.
• 3.1.2 Patients must not have received prior treatment (i.e., no induction chemotherapy).
• 3.1.3 Patients must have evaluable disease (per RECIST v1.1 response criteria). See Section 6.
• 3.3 for the evaluation of measurable disease.
• 3.1.4 Patients must be age ≥ 18 years.
• 3.1.5 Patients must have AJCC 8 th edition Stage I-II disease, as defined by a T-classification of T1-3, and N-classification of N1-2, without metastases (M0), as defined by physical examination (including nasopharyngolaryngoscopy) and positron emission tomography (PET).
• 3.1.6 Patient must receive a staging PET scan prior to registration on study.
• 3.1.7 Patients must exhibit an ECOG performance status of 0-1. Please refer to Appendix A ECOG Performance Status Scale.
• 3.1.8 Patients may be planned to undergo RT alone or RT with concurrent chemotherapy, with chemotherapy managed at the discretion of the treating medical oncologist per standard of care.
• 3.1.9 RT is known to be teratogenic to a developing human fetus. For this reason, patients of child-bearing potential (POCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; surgical methods (e.g. tubal ligation); abstinence) from time of informed consent, for the duration of study participation (while actively receiving RT. Should a patient become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately for consideration of cessation of RT. NOTE: A POCBP is any patient (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: • Has not undergone a hysterectomy or bilateral oophorectomy • Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months)
• 3.1.10 POCBP must have a negative pregnancy test prior to CT simulation or sign the Department of Radiation Oncology's standard pregnancy testing declination form. Note: the timing of the pregnancy test/declination form will follow the standard policy of the Department of Radiation Oncology, which requires completion of pregnancy testing or signed pregnancy declination prior to CT simulation.
• 3.1.11 Patients must have the ability to understand and the willingness to sign a written informed consent document prior to registration.

You cannot join if

• 3.2.1 Patients with cT4, cN3, or cM1 disease by AJCC 8 th edition.
• 3.2.2 Patients who have had prior RT to the head/neck region that would result in overlap of RT fields.
• 3.2.3 Patients who have had prior major surgery to the head/neck region that could disrupt lymphatic flow as determined by the PI.
• 3.2.4 Patients who have an uncontrolled intercurrent illness that would interfere with the receipt of RT including, but not limited to any of the following, are not eligible: • Uncontrolled connective tissue disorders (e.g. lupus, scleroderma) given potential for this to interfere with RT • Psychiatric illness/social situations that would limit compliance with study requirements • Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

Treatments listed in the registry

• Computed Tomography (Procedure): Undergo CT
• Nasopharyngeal Laryngoscopy (Procedure): Undergo nasopharyngolaryngoscopy
• Positron Emission Tomography (Procedure): Undergo PET
• Questionnaire Administration (Other): Ancillary studies
• Radiation Therapy (Radiation): Undergo radiation therapy

Na · Single Group · masking: None

As the registry describes them. Requirements to join, such as a tissue sample, are in the eligibility list above even when on-study procedures are optional. Ask the study team which steps apply to you.

• CT scans: Part of the study plan
• PET scans: Part of the study plan
• questionnaires: Part of the study plan
• radiation: Part of the study plan

Main goals

• 2-year locoregional progression free survival (From the beginning of radiation therapy to the first incidence of local recurrence, regional recurrence in the neck, or death, assessed at 2 years post-treatment)

Other goals

• 2-year PFS
• 2-year regional failure in the low-dose elective neck region
• 2-year overall survival (OS)
• Incidence of physician-reported adverse events (AEs)
• Incidence of patient-reported adverse events

Planned enrollment: 100 (estimated).

• Northwestern University, Chicago, Illinois
• Northwestern Medicine Warrenville, Warrenville, Illinois

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT07178301

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Jul 13, 2026. Public record; not medical advice.